Holen Sie sich die Stockscreener-App
91.00
1.61%
1.44
Vorhandelsmarkt:
90.20
-0.80
-0.88%
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals (RYTM) Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress - simplywall.st
Proposed sale of 64,540 common shares under registered plan (RYTM) - Stock Titan
HC Wainwright Issues Negative Estimate for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals (RYTM) CAO exercises RSUs, withholds shares for taxes - Stock Titan
Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
RYTM (NASDAQ: RYTM) brokered notice for 35,460-share sale on 03/03/2026 - Stock Titan
Does Rhythm Pharmaceuticals (RYTM) Share Price Reflect Its Obesity Treatment Potential Today - simplywall.st
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) CFO exercises options, acquiring 6,099 shares - Stock Titan
Canaccord Genuity Lowers Price Target for RYTM, Maintains Buy Ra - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Lowered to $140.00 at Canaccord Genuity Group - MarketBeat
HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $110.00 - MarketBeat
RYTM: HC Wainwright & Co. Lowers Price Target Despite Maintainin - GuruFocus
Why Is Rhythm Pharmaceuticals Stock Trading Higher Today?Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Robust Analyst Ratings Signal Potential 51.69% Upside - DirectorsTalk Interviews
Canaccord lowers Rhythm Pharmaceuticals stock price target to $140 - Investing.com
Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction - marketscreener.com
Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity - TipRanks
Rhythm Pharmaceuticals posts 18.8% placebo‑adjusted BMI reduction in TRANSCEND Phase 3 52‑week data - TradingView
Rhythm Pharmaceuticals (Nasdaq: RYTM) adds positive Phase 3 HO data ahead FDA PDUFA - Stock Titan
Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential - Sahm
Rhythm Pharmaceuticals (RYTM) Reveals Promising Phase 3 Trial Da - GuruFocus
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance
Rhythm Pharmaceuticals says PDUFA goal date for setmelanotide is March 20, 2026 - marketscreener.com
Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026 - TradingView
Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan
Artisan Partners Limited Partnership Buys 62,362 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
RYTM SEC FilingsRhythm Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
Rhythm Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-02-27 - Seeking Alpha
Wells Fargo & Company Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $136.00 - MarketBeat
Rhythm Pharmaceuticals (RYTM) Price Target Lowered by Wells Farg - GuruFocus
RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $140 From $145, Maintains Outperform Rating - marketscreener.com
Citizens Jmp Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $176.00 - MarketBeat
Is Rhythm Pharmaceuticals Inc. stock risky to hold now2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Needham & Company LLC Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Guggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
RYTM Stock Update: Guggenheim Maintains 'Buy', Raises Price Targ - GuruFocus
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook - Investing.com Nigeria
Rhythm Pharmaceuticals (RYTM) Financials 2026Income Statement and Balance Sheet - MarketBeat
Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Rhythm Pharmaceuticals files for mixed shelf - marketscreener.com
Rhythm Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock. - Bitget
Rhythm Pharmaceuticals Files For Mixed Shelf - TradingView
Rhythm Pharmaceuticals Inc (RYTM) Q4 2025 Earnings Call Highligh - GuruFocus
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target - Investing.com Nigeria
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target By Investing.com - Investing.com India
Earnings call transcript: Rhythm Pharmaceuticals beats Q4 2025 expectations - Investing.com
Rhythm Pharma Q4 2025 slides: revenue beats as HO launch nears - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Rhythm Pharma (RYTM) Earnings Call Transcript - AOL.com
Westfield Capital Management Co. LP Has $107.96 Million Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) Surpasses Revenue Expectations in Q4 - GuruFocus
Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q4 Net Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss - marketscreener.com
Vanguard Group Inc. Purchases 1,407,313 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q4 Revenue $57.3M, vs. FactSet Est of $56.2M - marketscreener.com
Rhythm Pharmaceuticals (RYTM) grows 2025 IMCIVREE revenue to $194.8M and narrows loss - Stock Titan
Primecap Management Co. CA Reduces Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business ... - Bluefield Daily Telegraph
BRIEF-Rhythm Pharmaceuticals Q4 Net Income USD -47.505 Million Vs. IBES Estimate USD -53.2 Million - TradingView
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewswire
Insights into Rhythm Pharmaceuticals Q4 Earnings - Sahm
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Mixed Share Price Performance - simplywall.st
A Look Ahead: Rhythm Pharmaceuticals's Earnings Forecast - Benzinga
Rhythm Pharma earnings in focus ahead of key obesity approval - Investing.com
Rhythm Pharmaceuticals Experiences Evaluation Revision Amidst Market Fluctuations and Strong Performance - Markets Mojo
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 42.11% Upside Potential with a Strong Buy Consensus - DirectorsTalk Interviews
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):